Ono Pharmaceutical Co. Ltd. has patented tricyclic prostaglandin E2 receptor EP3 subtype (PTGER3; EP3) agonists potentially useful for the treatment of renal diseases.

Work at Reactive Biosciences Inc. has led to the discovery of new phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer.

A D3 Bio (Wuxi) Co. Ltd. patent describes heterocyclic-substituted pyrimidopyran compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Chengdu Zeling Biomedical Technology Co. Ltd. has identified triazine compounds acting as NLRP3 inflammasome inhibitors.

Southern Research Institute and UAB Research Foundation have jointly described pyrazolopyrimidines acting as bromodomain-containing protein 4 (BRD4; HUNK1) and/or receptor-interacting serine/threonine-protein kinase 3 (RIPK3) and/or interleukin-6 (IL-6) inhibitors.

Atai Therapeutics Inc. has identified 3-alkylamine indole compounds acting as 5-HT2A receptor agonists and reported to be potentially useful for the treatment of anxiety, eating and neurological disorders.

Miralinc Pharma Inc. has patented new heterocyclic selective histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of type 2 Charcot-Marie-Tooth disease and chemotherapy-induced peripheral neuropathy, among others.

Humanwell Pharmaceutical US Inc. has synthesized new sigma non-opioid intracellular receptor 1 (SIGMAR1) antagonists reported to be useful for the treatment of cancer, pain, psychosis and substance abuse and dependence.

Quanta Therapeutics Inc. has prepared and tested new GTPase KRAS (G12D mutant) and GTPase KRAS (G12V mutant) inhibitors.

Betta Pharmaceuticals Co. Ltd. has prepared and tested probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) inhibitors reported to be useful for the treatment of cancer.